Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis

Anthony De Soyza, Timothy Aksamit

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: Non-cystic fibrosis bronchiectasis (NCFB) is an increasingly prevalent chronic respiratory disease, characterized by a cycle of infection and inflammation. It is progressive and associated with poor quality of life, increasing healthcare costs and mortality. Inhaled antibiotics offer the potential to decrease long-term bacterial burden and reduce or delay exacerbations which are a key driver of disease progression and healthcare costs. Currently however, no inhaled treatments are approved for the prevention of exacerbations in patients with NCFB. Areas covered: We consider current evidence for inhaled treatment in NCFB and discuss ciprofloxacin dry powder for inhalation (DPI), a novel treatment using PulmoSphere™ technology, delivered via a pocket-sized, breath-actuated inhaler. We also detail the unique features of the ongoing Phase 3 RESPIRE trials for ciprofloxacin DPI. Expert opinion: The simplicity of use and short administration time could make ciprofloxacin DPI an attractive treatment option with potential to reduce the number of exacerbations in patients with NCFB. The RESPIRE studies are the largest carried out in NCFB to date and will provide a benchmark for future trial design. If approved, following successful Phase 3 data, ciprofloxacin DPI has potential for significant use in NCFB due to its good tolerability and low treatment burden.

Original languageEnglish (US)
Pages (from-to)875-884
Number of pages10
JournalExpert Opinion on Orphan Drugs
Volume4
Issue number8
DOIs
StatePublished - Aug 2 2016

Fingerprint

Bronchiectasis
Ciprofloxacin
Powders
Inhalation
Fibrosis
Health Care Costs
Therapeutics
Benchmarking
Cost of Illness
Nebulizers and Vaporizers
Expert Testimony
Disease Progression
Chronic Disease
Quality of Life
Anti-Bacterial Agents
Inflammation
Technology
Mortality
Infection

Keywords

  • antibiotics
  • Bronchiectasis
  • ciprofloxacin
  • Ciprofloxacin dry powder for inhalation (DPI)
  • inhaled antibiotics
  • NCFB

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. / De Soyza, Anthony; Aksamit, Timothy.

In: Expert Opinion on Orphan Drugs, Vol. 4, No. 8, 02.08.2016, p. 875-884.

Research output: Contribution to journalArticle

@article{346c097917f94d478d99ce2ae1c49ece,
title = "Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis",
abstract = "Introduction: Non-cystic fibrosis bronchiectasis (NCFB) is an increasingly prevalent chronic respiratory disease, characterized by a cycle of infection and inflammation. It is progressive and associated with poor quality of life, increasing healthcare costs and mortality. Inhaled antibiotics offer the potential to decrease long-term bacterial burden and reduce or delay exacerbations which are a key driver of disease progression and healthcare costs. Currently however, no inhaled treatments are approved for the prevention of exacerbations in patients with NCFB. Areas covered: We consider current evidence for inhaled treatment in NCFB and discuss ciprofloxacin dry powder for inhalation (DPI), a novel treatment using PulmoSphere™ technology, delivered via a pocket-sized, breath-actuated inhaler. We also detail the unique features of the ongoing Phase 3 RESPIRE trials for ciprofloxacin DPI. Expert opinion: The simplicity of use and short administration time could make ciprofloxacin DPI an attractive treatment option with potential to reduce the number of exacerbations in patients with NCFB. The RESPIRE studies are the largest carried out in NCFB to date and will provide a benchmark for future trial design. If approved, following successful Phase 3 data, ciprofloxacin DPI has potential for significant use in NCFB due to its good tolerability and low treatment burden.",
keywords = "antibiotics, Bronchiectasis, ciprofloxacin, Ciprofloxacin dry powder for inhalation (DPI), inhaled antibiotics, NCFB",
author = "{De Soyza}, Anthony and Timothy Aksamit",
year = "2016",
month = "8",
day = "2",
doi = "10.1080/21678707.2016.1196129",
language = "English (US)",
volume = "4",
pages = "875--884",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis

AU - De Soyza, Anthony

AU - Aksamit, Timothy

PY - 2016/8/2

Y1 - 2016/8/2

N2 - Introduction: Non-cystic fibrosis bronchiectasis (NCFB) is an increasingly prevalent chronic respiratory disease, characterized by a cycle of infection and inflammation. It is progressive and associated with poor quality of life, increasing healthcare costs and mortality. Inhaled antibiotics offer the potential to decrease long-term bacterial burden and reduce or delay exacerbations which are a key driver of disease progression and healthcare costs. Currently however, no inhaled treatments are approved for the prevention of exacerbations in patients with NCFB. Areas covered: We consider current evidence for inhaled treatment in NCFB and discuss ciprofloxacin dry powder for inhalation (DPI), a novel treatment using PulmoSphere™ technology, delivered via a pocket-sized, breath-actuated inhaler. We also detail the unique features of the ongoing Phase 3 RESPIRE trials for ciprofloxacin DPI. Expert opinion: The simplicity of use and short administration time could make ciprofloxacin DPI an attractive treatment option with potential to reduce the number of exacerbations in patients with NCFB. The RESPIRE studies are the largest carried out in NCFB to date and will provide a benchmark for future trial design. If approved, following successful Phase 3 data, ciprofloxacin DPI has potential for significant use in NCFB due to its good tolerability and low treatment burden.

AB - Introduction: Non-cystic fibrosis bronchiectasis (NCFB) is an increasingly prevalent chronic respiratory disease, characterized by a cycle of infection and inflammation. It is progressive and associated with poor quality of life, increasing healthcare costs and mortality. Inhaled antibiotics offer the potential to decrease long-term bacterial burden and reduce or delay exacerbations which are a key driver of disease progression and healthcare costs. Currently however, no inhaled treatments are approved for the prevention of exacerbations in patients with NCFB. Areas covered: We consider current evidence for inhaled treatment in NCFB and discuss ciprofloxacin dry powder for inhalation (DPI), a novel treatment using PulmoSphere™ technology, delivered via a pocket-sized, breath-actuated inhaler. We also detail the unique features of the ongoing Phase 3 RESPIRE trials for ciprofloxacin DPI. Expert opinion: The simplicity of use and short administration time could make ciprofloxacin DPI an attractive treatment option with potential to reduce the number of exacerbations in patients with NCFB. The RESPIRE studies are the largest carried out in NCFB to date and will provide a benchmark for future trial design. If approved, following successful Phase 3 data, ciprofloxacin DPI has potential for significant use in NCFB due to its good tolerability and low treatment burden.

KW - antibiotics

KW - Bronchiectasis

KW - ciprofloxacin

KW - Ciprofloxacin dry powder for inhalation (DPI)

KW - inhaled antibiotics

KW - NCFB

UR - http://www.scopus.com/inward/record.url?scp=84975270466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975270466&partnerID=8YFLogxK

U2 - 10.1080/21678707.2016.1196129

DO - 10.1080/21678707.2016.1196129

M3 - Article

VL - 4

SP - 875

EP - 884

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

IS - 8

ER -